Effect of smoking in heart failure
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Based on thorough research from Goldman-Cecil Medicine, Fuster and Hurst's The Heart (15th Ed.), and Braunwald's Heart Disease, here is a comprehensive overview of the effect of smoking in heart failure:
Effect of Smoking in Heart Failure
1. Smoking as a Risk Factor for Developing Heart Failure
Smoking contributes to HF primarily by accelerating the underlying cardiovascular diseases that cause it:
- Accelerated atherosclerosis → ischemic cardiomyopathy, the most common cause of HF
- Left ventricular hypertrophy and diastolic dysfunction: Cigarette smokers show a higher prevalence of LV hypertrophy and diastolic dysfunction compared to nonsmokers, independent of coronary heart disease or alcohol use
- Hypertension: Chronic smoking causes hypertension and cardiac remodeling
- Atrial fibrillation and ventricular arrhythmias: Smoking is associated with both, which can precipitate or worsen HF
- Peripheral arterial disease (5× increased risk) reduces exercise tolerance and worsens HF functional status
— Fuster and Hurst's The Heart, 15th Edition
2. Mechanisms of Cardiovascular Harm Relevant to HF
Oxidative Stress
The central mechanism. Cigarette smoke delivers a high load of oxidizing chemicals and reactive oxygen species (ROS), which:
- Reduce bioavailability of nitric oxide (NO)
- Deplete endogenous antioxidants
- Generate oxidized LDL, promoting atherogenesis and thrombogenesis
Endothelial Dysfunction
- Smoking suppresses endothelial nitric oxide synthase (eNOS) expression → decreased NO
- NO is critical for vasodilation, inhibition of platelet aggregation, and prevention of smooth muscle proliferation
- In HF, where cardiac output is already reduced, further impaired coronary and peripheral vasodilation significantly worsens hemodynamics
Peripheral Vasoconstriction (Direct Hemodynamic Effect in HF)
"Smoking causes peripheral vasoconstriction, which is detrimental in heart failure." — Goldman-Cecil Medicine
This is especially harmful in HF with reduced ejection fraction (HFrEF), where the heart is already struggling against elevated afterload.
Prothrombotic State
- Increased platelet aggregation
- Elevated fibrinogen and von Willebrand factor
- Reduced tissue plasminogen activator (tPA)
- Trigger of thromboxane A₂ release (potent vasoconstrictor) and inhibition of prostacyclin
- These promote coronary thrombosis, precipitating acute HF decompensation
Plaque Rupture
- Smoking thins the fibrous cap (↓ n-prolyl-4-hydroxylase), increases matrix metalloproteinase (MMP) activity, and raises extracellular plaque content — all increasing vulnerability to plaque rupture and acute MI, a leading cause of de novo or worsening HF
3. Effect on Established Heart Failure
- Smoking cessation results in clinical improvement and reduced mortality in patients with HFrEF — a well-established finding supported by multiple studies
- Smoking increases the risk of recurrent ventricular tachyarrhythmias and hospitalization in post-MI patients with LV dysfunction
- Ongoing smoking in HF patients is associated with worsening functional capacity and increased mortality
4. Smoking Cessation in HF Patients
| Agent | Safety in HF |
|---|---|
| Nicotine replacement therapy (NRT) | Believed to be safe |
| Bupropion | Uncertain; known to raise blood pressure — use with caution |
| Varenicline | May increase cardiovascular risk; caution advised |
Smoking cessation is recommended as part of standard HF management, alongside treating hypertension, dyslipidemia, achieving optimal weight, and regular exercise. — Goldman-Cecil Medicine
5. Secondhand Smoke
Even passive exposure carries risk — associated with a 25–30% increased risk of coronary heart disease and stroke in non-smokers, along with acute endothelial dysfunction and platelet activation that can trigger ischemic events in vulnerable HF patients. — Fuster and Hurst's The Heart, 15th Edition
Summary: Smoking damages the heart through oxidative stress, endothelial dysfunction, vasoconstriction, and a prothrombotic state — all of which are particularly harmful in HF. It worsens LV function, promotes arrhythmias, and increases mortality. Cessation is a Class I lifestyle intervention in all HF guidelines, and NRT is the preferred pharmacologic aid given the uncertain safety profiles of bupropion and varenicline in this population.
This is a shared conversation. Sign in to Orris to start your own chat.